| Title |
NEW TREATMENT FOR AMYOTROPHIC LATERAL SCLEROSIS (LOU GEHRIG'S DISEASE |
| Subject |
Clinical Trials as Topic; Amyotrophic Lateral Sclerosis; Riluzole; Anticonvulsants; Academic Medical Centers; Hospitals, University; Public Relations; Communications Media; Mass Media; Social Marketing; Information Dissemination; News; Press Release; Lou Gehrig Disease |
| Description |
The preliminary analysis of a clinical trial of the drug riluzole, announced yesterday, shows it to be the first drug to have any impact on Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig's Disease. Generally, patients survive three to five years after diagnosis of the disease. A preliminary study indicated that patients who received the drug saw an increase in survival of approximately three months. |
| Publisher |
University of Utah Health Care Office of Public Affairs and Marketing |
| Date |
1995-04-05 |
| Language |
eng |
| Relation |
University of Utah Health Care Office of Public Affairs and Marketing Collection |
| Rights Management |
Copyright 2012 |
| Holding Institution |
Spencer S. Eccles Health Sciences Library, University of Utah |
| Scanning Technician |
sg |
| Relation is Part of |
Press Releases; University of Utah Health Sciences Center News |
| Type |
Text |
| ARK |
ark:/87278/s667183t |
| Setname |
ehsl_pahsc |
| ID |
935393 |
| Reference URL |
https://collections.lib.utah.edu/ark:/87278/s667183t |
